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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S477C8, C12, C15, C16, C18 linear alkyl amines and a benzyl amine, were
tested for the inhibitory activity against ChC. The inhibitor potency
showed to be directly correlated to the length of the alkyl chain. The C16
alkyl amide derivative HYADD4 was identiﬁed as lead compound (Ki¼
6.21.6 mM), on the basis of the best compromise between potency and
solubility.
With the aim of assessing the speciﬁcity of the effect, HYADD4 was
then screened vs 10 different human MMP catalytic subunits, showing
higher selectivity for MMP8 and MMP13. The Ki against human MMP13
was found to be in the micromolar range (61.7  7.0 mM).
Finally, since MMP13, unlike MMP8, is involved in OA progression, an ex
vivo study was performed by incubating HYADD4 in SF from patients
with inﬂammatory arthritis: the Ki value obtained (106.1  9.2 mM) was
comparable to that observed in vitro, thus validating the inhibitory
activity against MMP13.
Conclusions: These data suggest that the extremely hydrophobic side
chain of HYADD4, whose water solubility is boosted by the HA back-
bone, is pivotal in the mechanism of MMP competitive inhibition.
The polymer structure suggests that the alkyl side chain could easily
and selectively dock the hydrophobic S1’ pocket in the MMP catalytic
domain.
The hexadecyl derivative shows the best performance against MMP13
and MMP8, as conﬁrmed also in an ex-vivo experiment in SF vs human
MMP13. Furthermore, the intra-articular administration of the alkyl-
modiﬁed HA as a treatment for OA, thanks to its site-selectivity and
solubility, can overcome the common issues of the small molecule MMP
inhibitors, such as systemic distribution and toxicity.
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Purpose: Polyacrylamide hydrogel (PAAG) is an inert, non-degradable,
non-immunogenic polymer gel with high viscoelasticity consisting of
97.5% sterile water and 2.5% cross-linked polyacrylamide. Its bio-
compatibility in soft tissues has been demonstrated. PAAG has recently
been tested for the treatment of osteoarthritis (OA) in horses with
highly encouraging results; however no standardized experimental
studies have been done to explore its efﬁcacy. The purpose of this study
was to evaluate PAAG in the treatment of induced OA in a goat model.
Methods: A randomized controlled study was conducted involving
goats with induced OA on the left stiﬂe (knee) joint. OA was surgically
induced by the transection of the medial collateral ligament, the
bisection of the medial meniscus at its midpoint and partial-thickness
incisions of the cartilage of the medial tibial plateau. Goats were
allowed free exercise, and 3 months after surgery they were randomly
divided into 2 groups: group 1 (n¼ 4): PAAG and group 2 (n¼ 2): saline
solution (control). Treatments were injected intraarticularly. MRI of the
left knee had been performed prior to surgery, at the time of injection (3
months) and 4, 5 and 7 months post-surgery. T1, T2/PD and Stir
weighted MRI images were used to assess OA. All goats were clinically
evaluated on ground and on treadmill and videotaped for evaluation by
3 blinded observers. Haematology, biochemistry and acute phase pro-
teins were also assessed. The goats were euthanized 7 months after
surgery, and gross pathology and histopathology, including immuno-
histochemistry for nerve endings (n ¼ 3 joints), were performed on
both femorotibial joints. The hardness of the joint capsule was meas-
ured in both groups using Instron  5564 testing system (HIS Global-
Spec, MA, USA).
Results: At the end of the study, 75 % of the goats treated with PAAG
were clinically sound, and 25 % of them had not improved, whereas the
2 control goats were still lame. In both groups, the values of haema-
tology, biochemistry, or acute phase proteins werewithin normal range.
MRI showed that in group one, 3 out of 4 goats had a decrease followed
by a stabilization of OA lesions, while 1 goat had a mild progression of
the OA lesions. In group 2, both goats had a mild or marked increase ofOA lesions. Gross pathology inspection in group 1 demonstrated that all
the operated knees showed typical signs of OA. The inner synovial lining
was thickened, and the cartilage surface was uneven in all cases. The gel
was seen in various amounts adhering to the inner side of the joint
capsule in all the goats of group 1. Gross inspection of both goats in
group 2 also showed cartilage lesions and synovial thickening, but the
histopathological investigations revealed this to be more prominent in
group 1 than in group 2. It comprised angiogenesis, collagen and
synovial cell increase, and in the injected goats, also the gel. The nerve
endings were normal looking and in normal numbers. The investigation
of the joint capsule hardness showed that in the treated knee of the
goats of group 1, the medial side (injected with PAAG) was always less
hard than the lateral side.
Conclusions: This study demonstrated the efﬁcacy of a novel treat-
ment of OA, with 75 % of the goats treated with PAAG being clinically
sound. Treatment with PAAG did not have any inﬂuence on haema-
tology, biochemistry, or acute phase proteins. It induced a moderate
synovial hyperplasia of the inner side of the capsule with trapped
(integrated) gel, increased angiogenesis and collagen production. Pre-
liminary pathology and joint capsule hardness data suggest that PAAG
might act mainly on the joint soft tissue and especially the synovial
membrane. PAAG might have 2 effects on OA joints: 1- Joint capsule
was less hard on the treated (medial) than on the non-treated (lateral)
side and had a lower hardness when compared to group 2. OA joints
typically show joint stiffness - a major source of pain in OA. By
decreasing the joint capsule hardness, and thus joint stiffness, PAAG
might relieve the pain in the OA joint (“disease-modifying” effect). 2-
MRI and pathology investigations have revealed a stabilization of OA
lesions in the goats of group 1, which might be explained by the
mechanical effect through the high viscosupplementation provided by
PAAG that was still present in the joint cavity (“disease-stabilizing”
effect). No adverse reaction was seen following intraarticular injection
of PAAG. More investigations are needed to fully understand the
mechanism of action of PAAG in improving clinical signs and in sta-
bilizing OA. This pilot study may be used as a basis for further studies
using larger animal numbers.
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Purpose: One of the major problems in treatment of osteoarticular
diseases is to reach cells inside the matrix to provide drug. Indeed,
cartilage is an avascular tissue with a few cells feed by diffusion through
a dense protein network (collagens, glycosaminoglycans). In this work
we have designed polymeric nanoparticles (NPs) of poly (D, L-lactic/glycolic acid)(PLGA) synthesized by a double emulsion method, which
are biocompatible, biodegradable and can encapsulate water-soluble
agents. Our NPs are labelled with BSA coupled to a ﬂuorescent dye
(Cyanine-3) to follow them by epiﬂuorescent microscopy. As articular
